000861681 001__ 861681
000861681 005__ 20210130000936.0
000861681 0247_ $$2doi$$a10.1055/a-0807-8137
000861681 0247_ $$2ISSN$$a0029-5566
000861681 0247_ $$2ISSN$$a2567-6407
000861681 0247_ $$2pmid$$apmid:30769368
000861681 0247_ $$2WOS$$aWOS:000459505900001
000861681 037__ $$aFZJ-2019-02118
000861681 082__ $$a610
000861681 1001_ $$0P:(DE-HGF)0$$aTatsch, Klaus$$b0$$eCorresponding author
000861681 245__ $$aSPECT-Untersuchungen mit dem 123I-markierten Dopamintransporter-Liganden FP-CIT (DaTSCANTM)
000861681 260__ $$aStuttgart$$bThieme$$c2019
000861681 3367_ $$2DRIVER$$aarticle
000861681 3367_ $$2DataCite$$aOutput Types/Journal article
000861681 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1553883005_25990
000861681 3367_ $$2BibTeX$$aARTICLE
000861681 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000861681 3367_ $$00$$2EndNote$$aJournal Article
000861681 520__ $$aThe aim of the S1 guideline is to assist in establishing the indication and in performing, interpreting and reporting SPECT investigations of the dopamine transporter (DAT) with DaTSCANTM. Compared to the preceding version dated from 2007 the current update considers relevant new publications, the guidelines of the European (EANM) and Society of Nuclear Medicine (SNM), and the current version of the S3 guideline of the German Society of Neurology on „Idiopathic Parkinsonsian Syndrome“. In addition new technical developments are incorporated.
000861681 536__ $$0G:(DE-HGF)POF3-573$$a573 - Neuroimaging (POF3-573)$$cPOF3-573$$fPOF III$$x0
000861681 588__ $$aDataset connected to CrossRef
000861681 7001_ $$aBuchert, Ralph$$b1
000861681 7001_ $$aBartenstein, Peter$$b2
000861681 7001_ $$aBarthel, Henryk$$b3
000861681 7001_ $$aBoecker, Henning$$b4
000861681 7001_ $$aBrust, Peter$$b5
000861681 7001_ $$0P:(DE-Juel1)177611$$aDrzezga, Alexander$$b6$$ufzj
000861681 7001_ $$ala Fougère, Christian$$b7
000861681 7001_ $$aGründer, Gerhard$$b8
000861681 7001_ $$aGrünwald, Frank$$b9
000861681 7001_ $$aKrause, Bernd-J.$$b10
000861681 7001_ $$aKuwert, Torsten$$b11
000861681 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b12$$ufzj
000861681 7001_ $$aRominger, Axel$$b13
000861681 7001_ $$aSabri, Osama$$b14
000861681 7001_ $$aSchreckenberger, Mathias$$b15
000861681 7001_ $$aMeyer, Philipp T.$$b16
000861681 773__ $$0PERI:(DE-600)2030804-8$$a10.1055/a-0807-8137$$gVol. 58, no. 01, p. 5 - 16$$n01$$p5 - 16$$tNuklearmedizin$$v58$$x2567-6407$$y2019
000861681 909CO $$ooai:juser.fz-juelich.de:861681$$pVDB
000861681 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177611$$aForschungszentrum Jülich$$b6$$kFZJ
000861681 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b12$$kFZJ
000861681 9131_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000861681 9141_ $$y2019
000861681 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNUKLEARMED-NUCL MED : 2017
000861681 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000861681 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000861681 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000861681 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000861681 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000861681 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000861681 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000861681 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000861681 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x0
000861681 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000861681 980__ $$ajournal
000861681 980__ $$aVDB
000861681 980__ $$aI:(DE-Juel1)INM-2-20090406
000861681 980__ $$aI:(DE-Juel1)INM-4-20090406
000861681 980__ $$aUNRESTRICTED